Agilent Technologies, Inc. (NYSE:A) had its price objective upped by Barclays PLC from $67.00 to $71.00 in a research report sent to investors on Tuesday. The brokerage currently has an overweight rating on the medical research company’s stock.
Several other equities research analysts also recently commented on the company. BidaskClub downgraded Agilent Technologies from a strong-buy rating to a buy rating in a report on Saturday, August 12th. Zacks Investment Research downgraded Agilent Technologies from a buy rating to a hold rating in a report on Thursday, November 16th. Janney Montgomery Scott increased their price objective on Agilent Technologies from $65.00 to $70.00 and gave the company a buy rating in a report on Wednesday, August 16th. J P Morgan Chase & Co increased their price objective on Agilent Technologies to $75.00 and gave the company an overweight rating in a report on Tuesday. Finally, Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $68.00 price objective on shares of Agilent Technologies in a report on Tuesday, September 26th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Agilent Technologies has an average rating of Buy and a consensus target price of $68.20.
Agilent Technologies (NYSE A) opened at $69.91 on Tuesday. Agilent Technologies has a 12-month low of $42.92 and a 12-month high of $70.81. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.76 and a current ratio of 3.22. The firm has a market capitalization of $22,515.09, a P/E ratio of 29.52, a price-to-earnings-growth ratio of 2.75 and a beta of 1.27.
WARNING: “Agilent Technologies, Inc. (A) Given New $71.00 Price Target at Barclays PLC” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/22/agilent-technologies-inc-a-given-new-71-00-price-target-at-barclays-plc.html.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be given a $0.149 dividend. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.85%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s dividend payout ratio (DPR) is presently 25.24%.
In related news, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $70.00, for a total value of $1,573,670.00. Following the transaction, the chief executive officer now owns 327,882 shares in the company, valued at $22,951,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Boon Hwee Koh sold 4,500 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total value of $286,335.00. The disclosure for this sale can be found here. Insiders sold 107,709 shares of company stock worth $7,195,576 in the last 90 days.
A number of large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio boosted its stake in Agilent Technologies by 0.9% in the third quarter. Public Employees Retirement System of Ohio now owns 394,744 shares of the medical research company’s stock valued at $25,343,000 after buying an additional 3,452 shares in the last quarter. Coastline Trust Co boosted its stake in Agilent Technologies by 20.1% in the third quarter. Coastline Trust Co now owns 10,280 shares of the medical research company’s stock valued at $660,000 after buying an additional 1,720 shares in the last quarter. Hahn Capital Management LLC boosted its stake in Agilent Technologies by 1.0% in the third quarter. Hahn Capital Management LLC now owns 598,781 shares of the medical research company’s stock valued at $38,442,000 after buying an additional 5,648 shares in the last quarter. Americafirst Capital Management LLC acquired a new stake in Agilent Technologies in the third quarter valued at about $743,000. Finally, IFM Investors Pty Ltd acquired a new stake in Agilent Technologies in the third quarter valued at about $596,000.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
What are top analysts saying about Agilent Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agilent Technologies Inc. and related companies.